Efficacy and safety of GLP-1 receptor agonists in patients with obesity: 23 (6), 14691478
We use advanced bloodwork to track IGF-1, blood sugar, and lipids so your progress is based on data, not guesswork
Tailored Solutions for GLP-1 RA Research for GLP-1 RA Research Whether you're studying weight loss efficacy, glycemic control, cardiovascular outcomes, or quality of life improvements, Signant Health's ePRO solutions deliver: Robust data collection for primary and secondary endpoints Expert input from our team of 50+ clinicians and COA scientists to drive highest quality evidence generation Evidence generation to support for health technology assessments and economic evaluations 24/7 global patient and site support Seamless integration of decentralized trial elements, such as eConsent, TeleVisits, and more
Clinicians must carefully evaluate individual patient risk factors, particularly personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2), before prescribing these agents
Subacute encephalopathy with seizures in alcoholics (SESA) syndrome: Relevant questions